DRTS News and Press, Alpha Tau Medical Ltd. From 10/16/25

2025-10-16 11:55:45 ET Intro Alpha Tau Medical ( DRTS ) is pioneering the first and (as far as we are aware) only way of delivering alpha particle radiation locally to solid tumors. While the company is not currently well known, this represents a potentially significant breakthrough...

2025-09-03 10:09:27 ET Yi Chen from H.C. Wainwright issued a price target of $9.00 for DRTS on 2025-09-03 10:51:00. The adjusted price target was set to $9.00. At the time of the announcement, DRTS was trading at $3.5888. The overall price target consensus is at $7.00 wi...

2025-09-03 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for DRTS on September 3, 2025 10:51AM ET. The previous analyst recommendation was Buy. DRTS was trading at $3.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or me...

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present and meet investors in th...

Alpha Tau Medical Ltd. (DRTS) is expected to report $-0.12 for Q2 2025

2025-08-11 16:28:11 ET More on Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical Read the full article on Seeking Alpha For further det...

- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot studies, positioned for imminent pati...

2025-06-23 17:08:13 ET More on Alpha Tau Medical Oramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical ...

JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will present at the Jefferies Global H...